Immuron targets cash injection
The halt will remain in place until Tuesday 13th June 2017.
Company
Immuron Ltd
ASX:IMC
Immuron Ltd (ASX:IMC, NASDAQ:IMRN) is focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
71 stories · page 3 of 4
Immuron looks to NASDAQ
The halt will remain in place until Thursday 1st June 2017.
Immuron gets ready to begin clinical trial of new drug candidate
CDI causes an estimated annual economic cost of more than US$10 billion.
Immuron enrols first patient in paediatric fatty liver trial in the U.S.
Pediatric NAFLD is a progressive form of liver disease.
Immuron watches several high-value NASH related deals
Microbiome company Immuron (ASX:IMC) is witnessing a series of high-value licensing merger & acquisition (LM&A) deals related to NASH (non-alcoholic steatohepatitis) assets.